Eszopiclone

Generic Name: Eszopiclone

Brand Names: Lunesta

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₇ClN_₆O_₃

CAS Number: 138729-47-2

Unique Ingredient Identifier: UZX80K71OE

Background: Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as cyclopyrrolones. Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a safer alternative to other drugs used for insomnia.

One major benefit of eszopiclone is that it is approved by the FDA for the long-term treatment of insomnia. This sets it apart from many other hypnotic sedatives, which are generally approved only for the relief of short-term (6-8 weeks) insomnia. Eszopiclone was initially approved by the FDA in 2004.

Indication: Eszopiclone is indicated for the treatment of insomnia.

Associated Conditions: Insomnia

Clinical Trials

Continuous Positive Airway Pressure (CPAP) Promotion And Prognosis - the Army Sleep Apnea Program (ASAP)

Phase 4

Completed

Conditions: Obstructive Sleep Apnea

Interventions: Drug: Placebo control
Drug: Eszopiclone

First Posted Date: 2008-02-11

Last Posted Date: 2009-02-26

Lead Sponsor: Walter Reed Army Medical Center

Target Recruit Count: 154

Registration Number: NCT00612157

Locations: 🇺🇸
Walter Reed Army Medical Center, Washington, District of Columbia, United States

Eszopiclone for Improving Sleep in Multiple Sclerosis (MS)

Not Applicable

Completed

Conditions: Relapsing Remitting Multiple Sclerosis
Sleep Initiation and Maintenance Disorders
Fatigue

Interventions: Other: placebo
Drug: eszopiclone

First Posted Date: 2008-01-15

Last Posted Date: 2009-01-05

Lead Sponsor: University of Vermont

Target Recruit Count: 30

Registration Number: NCT00594087

Locations: 🇺🇸
University of Vermont, Burlington, Vermont, United States

Sleep Loss and Mechanisms of Impaired Glucose Metabolism

Not Applicable

Completed

Conditions: Primary Insomnia

Interventions: Drug: placebo
Drug: eszopiclone

First Posted Date: 2007-11-09

Last Posted Date: 2013-12-10

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 20

Registration Number: NCT00555750

Locations: 🇺🇸
Brigham and Women's Hospital, Division of Sleep Medicine, Boston, Massachusetts, United States

Mindfulness Versus Pharmacotherapy for Chronic Insomnia: A Pilot Study

Phase 2

Completed

Conditions: Chronic Insomnia
Primary Insomnia

Interventions: Behavioral: Mindfulness-Based Stress Reduction
Drug: eszopiclone

First Posted Date: 2007-08-13

Last Posted Date: 2013-03-29

Lead Sponsor: University of Minnesota

Target Recruit Count: 30

Registration Number: NCT00515177

Locations: 🇺🇸
Minnesota Regional Sleep Disorders Center at Hennepin County Medical Center, Minneapolis, Minnesota, United States
🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States